Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd held its 34th Annual General Meeting on September 29, 2025, via video conferencing from 3:30 PM to 3:54 PM, with 34 members present. Chairman Mr. Vimal D. Shah and CFO Mr. Iqubal Patel led the proceedings, and Mr. Hemant Shetye served as the scrutinizer. Eight resolutions were transacted, including adoption of FY2024-25 audited financial statements, re-appointment of Mr. Praveen J. Bafna as a director, appointment of Ms. Sathya Venkatachalam as an Independent Director, and appointment of M/s HSPN & Associates as Secretarial Auditor. Key special resolutions covered a revision in remuneration for Executive Director Mr. Vimal D. Shah, an increase in the company's borrowing limits, authorization to sell or dispose of the company's undertaking, and an enhancement of investment limits under Section 186 of the Companies Act. The actual voting results were not disclosed in this filing and will be submitted separately within two working days.
Several special resolutions — including higher borrowing powers, ability to sell or dispose of major business assets, and a pay hike for the Executive Director — could meaningfully affect the company's financial flexibility and capital structure, pending shareholder approval results. Shareholders should watch for the forthcoming voting outcome to see whether these proposals passed.